Table 1.

Patients receiving varenicline for smoking reduction and resulting effects on drug-induced movement disorders

Patient, Age (yr)/Sex	Diagnosis/ Antipsychotic	Measure	Study visit
			Screen Week 0	Baselinea Week 2	Week 3	Quit date Week 6	Week 8	Week 10	Week 12
65/Male	Schizophrenia/ Paliperidone	TLFBb	7	20	20	10
		COc	18	7	10	5
		AIMSd	16	12	17	14
		SASe	1	0		1
		BASf	6	5		6
47/Male	Schizophrenia/ Paliperidone	TLFB	10	10	10	10	4	4	3
		CO	13	11	9	14	9	6	5
		AIMS	6	5	6	8	8	6	5
		SAS	10	9		6			6
		BAS	5	5		5			4
65/Male	Schizophrenia/ Paliperidone	TLFB	14	14	8	5
		CO	27	33	6	14
		AIMS	4	6	4	4
		SAS	0	0		0
		BAS	0	0		0

^aVarenicline titration initiated at baseline, ^bTimeline-Follow Back mean daily cigarette consumption, ^cCarbon monoxide exhaled in parts per million (ppm), ^dAbnormal Involuntary Movement Scale, ^eSimpson Angus Scale, ^fBarnes Akathisia Scale.